Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.

Science · 2021 · PMC7963220 · PMID 33495306

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

fell just short of significanceno p-value reported

We found that plitidepsin significantly reduced genomic RNA content at 8 and 12 hours after infection and fell just short of significance at the 24-hour time point, similar to remdesivir treatment ( Fig. 3A ).

also in 102 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.